Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

2017755 citationsJournal Articlebronze Open Access

Authors

Jeffrey I. Weitz · McMaster University

Anthonie W.A. Lensing · Bayer (Germany)

Martin H. Prins · Maastricht University

Rupert Bauersachs · Thrombosis and Atherosclerosis Research Institute

Jan Beyer‐Westendorf · University Hospital Carl Gustav Carus

Henri Bounameaux · University of Geneva

Timothy Brighton

Abstract

Among patients with venous thromboembolism in equipoise for continued anticoagulation, the risk of a recurrent event was significantly lower with rivaroxaban at either a treatment dose (20 mg) or a prophylactic dose (10 mg) than with aspirin, without a significant increase in bleeding rates. (Funded by Bayer Pharmaceuticals; EINSTEIN CHOICE ClinicalTrials.gov number, NCT02064439 .).

Topics & Keywords

Venous Thromboembolism Diagnosis and Management Atrial Fibrillation Management and Outcomes Blood Coagulation and Thrombosis Mechanisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 376, Issue 13, pp. 1211-1222

DOI: 10.1056/nejmoa1700518

Field-Weighted Citation Impact: 86.47